102 related articles for article (PubMed ID: 9230206)
21. CD8+CD45RA+CD27-CD28-T-cell subset in PBL of cervical cancer patients representing CD8+T-cells being able to recognize cervical cancer associated antigens provided by HPV 16 E7.
Pilch H; Hoehn H; Schmidt M; Steiner E; Tanner B; Seufert R; Maeurer M
Zentralbl Gynakol; 2002; 124(8-9):406-12. PubMed ID: 12655469
[TBL] [Abstract][Full Text] [Related]
22. Antitumor activity of human papillomavirus type 16 E7-specific T cells against virally infected squamous cell carcinoma of the head and neck.
Albers A; Abe K; Hunt J; Wang J; Lopez-Albaitero A; Schaefer C; Gooding W; Whiteside TL; Ferrone S; DeLeo A; Ferris RL
Cancer Res; 2005 Dec; 65(23):11146-55. PubMed ID: 16322265
[TBL] [Abstract][Full Text] [Related]
23. Induction of specific CD8+ T-lymphocyte responses using a human papillomavirus-16 E6/E7 fusion protein and autologous dendritic cells.
Murakami M; Gurski KJ; Marincola FM; Ackland J; Steller MA
Cancer Res; 1999 Mar; 59(6):1184-7. PubMed ID: 10096544
[TBL] [Abstract][Full Text] [Related]
24. Human T-cell responses to HLA-A-restricted high binding affinity peptides of human papillomavirus type 18 proteins E6 and E7.
Rudolf MP; Man S; Melief CJ; Sette A; Kast WM
Clin Cancer Res; 2001 Mar; 7(3 Suppl):788s-795s. PubMed ID: 11300474
[TBL] [Abstract][Full Text] [Related]
25. Effect of human papillomavirus-16 infection on CD8+ T-cell recognition of a wild-type sequence p53264-272 peptide in patients with squamous cell carcinoma of the head and neck.
Sirianni N; Ha PK; Oelke M; Califano J; Gooding W; Westra W; Whiteside TL; Koch WM; Schneck JP; DeLeo A; Ferris RL
Clin Cancer Res; 2004 Oct; 10(20):6929-37. PubMed ID: 15501971
[TBL] [Abstract][Full Text] [Related]
26. Immunization strategy against cervical cancer involving an alphavirus vector expressing high levels of a stable fusion protein of human papillomavirus 16 E6 and E7.
Daemen T; Regts J; Holtrop M; Wilschut J
Gene Ther; 2002 Jan; 9(2):85-94. PubMed ID: 11857066
[TBL] [Abstract][Full Text] [Related]
27. Low-dose adenovirus vaccine encoding chimeric hepatitis B virus surface antigen-human papillomavirus type 16 E7 proteins induces enhanced E7-specific antibody and cytotoxic T-cell responses.
Báez-Astúa A; Herráez-Hernández E; Garbi N; Pasolli HA; Juárez V; Zur Hausen H; Cid-Arregui A
J Virol; 2005 Oct; 79(20):12807-17. PubMed ID: 16188983
[TBL] [Abstract][Full Text] [Related]
28. An improved rearranged Human Papillomavirus Type 16 E7 DNA vaccine candidate (HPV-16 E7SH) induces an E7 wildtype-specific T cell response.
Ohlschläger P; Pes M; Osen W; Dürst M; Schneider A; Gissmann L; Kaufmann AM
Vaccine; 2006 Apr; 24(15):2880-93. PubMed ID: 16472545
[TBL] [Abstract][Full Text] [Related]
29. Synthetic peptides induce a cytotoxic response against human papillomavirus type-18.
Castellanos MR; Hayes RL; Maiman MA
Gynecol Oncol; 2001 Jul; 82(1):77-83. PubMed ID: 11426965
[TBL] [Abstract][Full Text] [Related]
30. Both E7 and CpG-oligodeoxynucleotide are required for protective immunity against challenge with human papillomavirus 16 (E6/E7) immortalized tumor cells: involvement of CD4+ and CD8+ T cells in protection.
Kim TY; Myoung HJ; Kim JH; Moon IS; Kim TG; Ahn WS; Sin JI
Cancer Res; 2002 Dec; 62(24):7234-40. PubMed ID: 12499264
[TBL] [Abstract][Full Text] [Related]
31. Induction of tumor-specific CD4+ and CD8+ T-cell immunity in cervical cancer patients by a human papillomavirus type 16 E6 and E7 long peptides vaccine.
Welters MJ; Kenter GG; Piersma SJ; Vloon AP; Löwik MJ; Berends-van der Meer DM; Drijfhout JW; Valentijn AR; Wafelman AR; Oostendorp J; Fleuren GJ; Offringa R; Melief CJ; van der Burg SH
Clin Cancer Res; 2008 Jan; 14(1):178-87. PubMed ID: 18172269
[TBL] [Abstract][Full Text] [Related]
32. Human leukocyte antigen class I/II alleles and development of human papillomavirus-related cervical neoplasia: results from a case-control study conducted in the United States.
Hildesheim A; Schiffman M; Scott DR; Marti D; Kissner T; Sherman ME; Glass AG; Manos MM; Lorincz AT; Kurman RJ; Buckland J; Rush BB; Carrington M
Cancer Epidemiol Biomarkers Prev; 1998 Nov; 7(11):1035-41. PubMed ID: 9829713
[TBL] [Abstract][Full Text] [Related]
33. Immunization with human papillomavirus type 16 (HPV16) oncoprotein-loaded dendritic cells as well as protein in adjuvant induces MHC class I-restricted protection to HPV16-induced tumor cells.
De Bruijn ML; Schuurhuis DH; Vierboom MP; Vermeulen H; de Cock KA; Ooms ME; Ressing ME; Toebes M; Franken KL; Drijfhout JW; Ottenhoff TH; Offringa R; Melief CJ
Cancer Res; 1998 Feb; 58(4):724-31. PubMed ID: 9485027
[TBL] [Abstract][Full Text] [Related]
34. Viral recombinant vaccines to the E6 and E7 antigens of HPV-16.
He Z; Wlazlo AP; Kowalczyk DW; Cheng J; Xiang ZQ; Giles-Davis W; Ertl HC
Virology; 2000 Apr; 270(1):146-61. PubMed ID: 10772987
[TBL] [Abstract][Full Text] [Related]
35. Safety and immunogenicity of TA-HPV, a recombinant vaccinia virus expressing modified human papillomavirus (HPV)-16 and HPV-18 E6 and E7 genes, in women with progressive cervical cancer.
Kaufmann AM; Stern PL; Rankin EM; Sommer H; Nuessler V; Schneider A; Adams M; Onon TS; Bauknecht T; Wagner U; Kroon K; Hickling J; Boswell CM; Stacey SN; Kitchener HC; Gillard J; Wanders J; Roberts JS; Zwierzina H
Clin Cancer Res; 2002 Dec; 8(12):3676-85. PubMed ID: 12473576
[TBL] [Abstract][Full Text] [Related]
36. A recombinant vaccinia virus encoding human papillomavirus types 16 and 18, E6 and E7 proteins as immunotherapy for cervical cancer.
Borysiewicz LK; Fiander A; Nimako M; Man S; Wilkinson GW; Westmoreland D; Evans AS; Adams M; Stacey SN; Boursnell ME; Rutherford E; Hickling JK; Inglis SC
Lancet; 1996 Jun; 347(9014):1523-7. PubMed ID: 8684105
[TBL] [Abstract][Full Text] [Related]
37. HLA class I binding promiscuity of the CD8 T-cell epitopes of human papillomavirus type 16 E6 protein.
Nakagawa M; Kim KH; Gillam TM; Moscicki AB
J Virol; 2007 Feb; 81(3):1412-23. PubMed ID: 17108051
[TBL] [Abstract][Full Text] [Related]
38. Naturally processed and HLA-B8-presented HPV16 E7 epitope recognized by T cells from patients with cervical cancer.
Oerke S; Höhn H; Zehbe I; Pilch H; Schicketanz KH; Hitzler WE; Neukirch C; Freitag K; Maeurer MJ
Int J Cancer; 2005 May; 114(5):766-78. PubMed ID: 15609316
[TBL] [Abstract][Full Text] [Related]
39. The association of an HPV16 oncogene variant with HLA-B7 has implications for vaccine design in cervical cancer.
Ellis JR; Keating PJ; Baird J; Hounsell EF; Renouf DV; Rowe M; Hopkins D; Duggan-Keen MF; Bartholomew JS; Young LS
Nat Med; 1995 May; 1(5):464-70. PubMed ID: 7585096
[TBL] [Abstract][Full Text] [Related]
40. [Intracutaneous test for detection of cellular immune reactions to HPV-16 proteins in patients with CIN].
Heim K; Höpfl R; Sandbichler M; Sepp N; Wartusch B; Müller-Holzner E; Jochmus-Kudielka I; Ter Meulen J; Gissmann L; Fritsch P
Gynakol Rundsch; 1991; 31 Suppl 2():220-3. PubMed ID: 1665135
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
